Opinion|Videos|January 27, 2026
Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
Advertisement
A recent real‑world analysis presented at American Society of Hematology Annual Meeting (ASH 2025) examined “time toxicity” — the burden of frequent healthcare visits and therapy‑related appointments — in patients treated with Epcoritamab. The study compared fixed‑duration regimens (such as for some bispecific antibodies) to continuous, treat‑to‑progression approaches, such as CAR-T therapies.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
Online GLP-1 Sellers Often Skip Clinician Oversight
4
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
5